Information  X 
Enter a valid email address

Destiny Pharma PLC Ord 0.01 (DEST)

Date Time Source Announcement
09 Sep 2021 7:00 am
RNS
Interim results for six months ended 30 June 2021
23 Aug 2021 7:00 am
RNS
Notice of Interim Results
02 Aug 2021 7:00 am
RNS
Secondary endpoint analysis from Phase 2b trial
09 Jul 2021 8:00 am
RNS
XF-73 Phase 2b data to be presented at ECCMID
06 Jul 2021 7:00 am
RNS
NTCD-M3 RD Agreement with US Dept Veterans Affairs
02 Jul 2021 8:00 am
RNS
Scientific Advisor Gerding chairs C Diff symposium
29 Jun 2021 8:24 am
RNS
DEST to present at Shares & AJ Bell Webinar 6/7/21
10 Jun 2021 5:00 pm
RNS
Director Dealing
  7:00 am
RNS
XF-73 data abstract to be presented at 2021 ECCMID
07 Jun 2021 7:00 am
RNS
Destiny Pharma welcomes G7's Communique on AMR
03 Jun 2021 12:03 pm
RNS
Result of AGM
02 Jun 2021 7:00 am
RNS
Positive update on microbiome therapeutic NTCD-M3
25 May 2021 7:00 am
RNS
Further information re AGM
19 May 2021 7:00 am
RNS
Notice to Register for 2021 AGM
06 May 2021 10:00 am
RNS
Conference Attendance for May 2021
04 May 2021 7:00 am
RNS
Posting of Annual Report and Notice of AGM
30 Apr 2021 7:00 am
RNS
Director Dealing
23 Apr 2021 7:00 am
RNS
Director Dealing
15 Apr 2021 8:00 am
RNS
FY 2020 Investor Presentation
14 Apr 2021 7:00 am
RNS
Final Results
29 Mar 2021 12:45 pm
RNS
Exercise of Options and Total Voting Rights
  12:00 pm
RNS
Destiny Pharma to Join Equity Development Webinar
  11:06 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  9:06 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Destiny Pharma Reports Positive Phase 2b Results
16 Mar 2021 7:00 am
RNS
Notice of Results
15 Mar 2021 7:00 am
RNS
Destiny Pharma Announces Agreement with NIAID
10 Mar 2021 2:15 pm
RNS
Exercise of Options and Total Voting Rights
  7:00 am
RNS
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
10 Feb 2021 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
03 Feb 2021 7:00 am
RNS
Brazilian Patent Granted for XF-73 nasal gel
02 Feb 2021 7:05 am
RNS
Destiny Pharma to join panel discussion at LSX
  7:00 am
RNS
Destiny Pharma Appoints Professor Mark Wilcox
21 Jan 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  4:31 pm
RNS
Grant of Share Options
  8:28 am
RNS
Destiny Pharma Investor Presentation
14 Jan 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
07 Jan 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Destiny Pharma: Directors Dealings
06 Jan 2021 8:00 am
RNS
Destiny Pharma Appoints Stephanie Bewick as CBO
05 Jan 2021 7:00 am
RNS
Phase 2b trial of XF-73 completes recruitment
23 Dec 2020 2:09 pm
RNS
Grant of share options
22 Dec 2020 7:00 am
RNS
Update on the recently acquired NTCD-M3 programme
01 Dec 2020 5:23 pm
RNS
Holding(s) in Company
30 Nov 2020 2:00 pm
RNS
Holding(s) in Company
26 Nov 2020 10:50 am
RNS
Result of General Meeting and Total Voting Rights
25 Nov 2020 7:00 am
RNS
Result of Open Offer
09 Nov 2020 4:25 pm
RNS
Fundraising and Acquisition
12 Oct 2020 7:00 am
RNS
Clinical Study Patient Recruitment Update
17 Sep 2020 7:00 am
RNS
Interim results for the 6 months ended 30 Jun 2020
  7:00 am
RNS
Update on Phase 2b clinical study of XF-73
10 Sep 2020 7:00 am
RNS
Notice of Results
07 Sep 2020 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension

a d v e r t i s e m e n t